Research Analysts’ Recent Ratings Updates for PROCEPT BioRobotics (PRCT)

Several analysts have recently updated their ratings and price targets for PROCEPT BioRobotics (NASDAQ: PRCT):

• 12/18/2025 – PROCEPT BioRobotics had its price target lowered by analysts at Truist Financial Corporation from $50.00 to $47.00. They now have a “buy” rating on the stock.
• 12/14/2025 – PROCEPT BioRobotics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/12/2025 – PROCEPT BioRobotics was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “strong-buy” rating.
• 12/12/2025 – PROCEPT BioRobotics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $62.00 price target on the stock.
• 12/12/2025 – PROCEPT BioRobotics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $62.00 price target on the stock.
• 12/8/2025 – PROCEPT BioRobotics had its “neutral” rating reaffirmed by analysts at Bank of America Corporation. They now have a $38.00 price target on the stock, down previously from $55.00.
• 12/6/2025 – PROCEPT BioRobotics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/2/2025 – PROCEPT BioRobotics had its price target lowered by analysts at Morgan Stanley from $56.00 to $51.00. They now have an “overweight” rating on the stock.
• 11/8/2025 – PROCEPT BioRobotics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/5/2025 – PROCEPT BioRobotics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $50.00 price target on the stock, down previously from $55.00.
• 11/5/2025 – PROCEPT BioRobotics had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $55.00 price target on the stock.
• 11/5/2025 – PROCEPT BioRobotics had its price target lowered by analysts at Wells Fargo & Company from $58.00 to $51.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – PROCEPT BioRobotics had its price target lowered by analysts at TD Cowen from $85.00 to $50.00. They now have a “buy” rating on the stock.

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.